Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Single-arm, Single-center, Non-randomized, Open-label Study on the Application of Amyloid Imaging Agent [18F]Florbetaben(18FBB) PET/CT Imaging to Distinguish Non-cognitively Impaired Subjects and Mild to Moderate Alzheimer Disease Subjects in Chinese Population
Authors not listed
Sinotau Pharmaceutical Group · 2021
Abstract
This is a bridging study to visually and quantitatively assess PET images obtained after single application of 300 MBq \[18F\]florbetaben and PET scanning of patients with Alzheimer disease.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-11 MST
Cite this
APA
Anonymous. (2021). Single-arm, Single-center, Non-randomized, Open-label Study on the Application of Amyloid Imaging Agent [18F]Florbetaben(18FBB) PET/CT Imaging to Distinguish Non-cognitively Impaired Subjects and Mild to Moderate Alzheimer Disease Subjects in Chinese Population. <em>Sinotau Pharmaceutical Group</em>. https://clinicaltrials.gov/study/NCT05527288
Vancouver
Anonymous. Single-arm, Single-center, Non-randomized, Open-label Study on the Application of Amyloid Imaging Agent [18F]Florbetaben(18FBB) PET/CT Imaging to Distinguish Non-cognitively Impaired Subjects and Mild to Moderate Alzheimer Disease Subjects in Chinese Population. Sinotau Pharmaceutical Group. 2021.
BibTeX
@misc{anon2021Single,
title = {Single-arm, Single-center, Non-randomized, Open-label Study on the Application of Amyloid Imaging Agent [18F]Florbetaben(18FBB) PET/CT Imaging to Distinguish Non-cognitively Impaired Subjects and Mild to Moderate Alzheimer Disease Subjects in Chinese Population},
author = {Anonymous},
journal = {Sinotau Pharmaceutical Group},
year = {2021},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
University of Wisconsin, Madison 2019
Open access · US-GOV
Longitudinal Evaluation of [18-F]MK-6240 as a Novel Tau PET Radiotracer in Patients With Alzheimer's Disease Dementia or Mild Cognitive Impairment Compared to Healthy Volunteers
Optina Diagnostics Inc. 2022
Open access · US-GOV
Evaluation of Optina Retina Scans to Detect the Likeley Cerebral Amyloid Status (CAS) as Determined by Prospective PET Imaging
GE Healthcare 2009
Open access · US-GOV
A Principal Open-label Study to Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease
GeroScience 2025
Open access · CC-BY
Unraveling the link between frailty and Alzheimer’s disease biomarkers in patients with mild cognitive impairment
University of Pennsylvania 2014
Open access · US-GOV
[18F]-T807 PET/CT Imaging of Tau Pathology in Young Onset Focal Dementia
University of Pennsylvania 2022
Open access · US-GOV